PubMed Health⌕ Search

Biomedical subjects

J M Pascual

Publications and source records attributed to J M Pascual.

78 records · Page 5Linked to original sources

[Neonatal myasthenic syndromes].

INTRODUCTION: In the newborn, myasthenia can present either as transient neonatal myasthenia or as a congenital syndrome. At present at least 8 syndromes involving neonatal neuromuscular junction (NMJ) malfunction have been described; one caused by the passage of transplacental antibodies from mother to child, while all but one of the rest are inherited. Inheritance in all but two syndromes is autosomal recessive. One is an autosomal dominantly inherited illness; in another the mode of inheritance is not clear. The deficit in function of the NMJ is presynaptic in 3 instances, at the junctional gap in 1, and postsynaptic in at least 3 other syndromes. DEVELOPMENT: We will review the clinical symptoms, as well as neurophysiologic and genetic testing available for diagnosis. We explain how, at least, in some of the syndromes, one can begin appropriate therapy based on clinical, neurophysiological and simple pharmacological testing. CONCLUSION: However, in many cases, it becomes necessary to refer the patient or a tissue sample, usually an intercostal nerve muscle preparation, to one of the very few centers in the world where in vitro neurophysiologic, microstructural and genetic procedures leading to a more precise diagnosis can be performed.

Acetylcholine↗

[Cerebral palsy: prenatal risk factors].

Prenatal risk factors causing cerebral palsy (CP), here defined as a non-progressive motor abnormality of tone or posture, are much more numerous than once believed, when a great deal of brain injury was attributed to factors surrounding delivery. Scientific advances in genetics and biochemistry, as well as clinical technical advances in, for example, amniotic fluid examination or fetal neuroimaging, has permitted us to find a multiplicity of new etiologies causing neonatal encephalopathy, most of which were formerly attributed to perinatal hypoxia-ischemia. This article reviews an expanded list of etiologies, including asphyxia, which has been found to cause only 6-10% of CP in full term infants, and periventricular leukomalacia, which is associated with 30-50% of CP in premature births. We also review a few of the genetic causes of CP, which lead to metabolic encephalopathies in come cases, to congenital anomalies in others, and sometimes to both. We discuss maternal gestational or intrapartum infections which may affect the fetus by direct in utero contagion or by other less direct means. Inborn metabolic errors affecting the fetus, such as diabetes, are touched on, as are the effects of maternal medications or recreational drugs on the fetus. Finally, we briefly cite the curious phenomenon occurring in multiple births, namely the potential of CP in the surviving infant or infants were the others have died in utero.

Brain Injuries↗

[Type 1 glucose transporter (Glut1) deficiency: manifestations of a hereditary neurological syndrome].

AIM: To define this genetic syndrome. DEVELOPMENT: The constellation of infantile epilepsy, acquired microcephaly and hypoglychorrachia is characteristic of glucose transporter type 1 (Glut1) deficiency syndrome, a prototype neurometabolic disorder caused by inheritable mutations in the gene SLC2A1. All known mutations reduce the function of Glut1 in the blood brain barrier and thus limit brain glucose availability. As the cerebral metabolic rate for glucose increases during infancy, patients become gradually symptomatic, a phenomenon that underscores the importance of early diagnosis via lumbar puncture and treatment, which has meet with some success in ameliorating several --but not all-- features of the disease. CONCLUSION: The increasing number of mild phenotypic variants being described, owing to the improved awareness of the disease, has led to the consideration of Glut1 deficiency in the diagnosis of infantile seizures, mental retardation, familial epilepsy and movement disorders.

Animals↗

[Neurological phenocopying].

AIMS: To expand the -supposedly- narrow relationships that exist between genes and clinical syndromes by reflecting on several illustrative examples that disturb current simplistic genotype: phenotype correlations, and to explore a variety of biological mechanisms that account for this emerging phenomenon. DEVELOPMENT: Because it is well known that mutations in a single gene can give rise to numerous phenotypes, it would appear, at least intuitively, that the converse relationship might also hold true: that different genotypes may converge on just one single phenotype. Several examples taken from the study of selected neurological diseases illustrate that the latter principle indeed occurs in nature because disparate human genetic anomalies manifest similarly by exhibiting only a relatively limited phenotypic repertoire. This interesting biological phenomenon and vexing clinical problem is best described as phenocopying. Conditions such as spinal muscular atrophy, congenital glycosylation disorders, and mitochondrial diseases are but a few notorious examples of phenocopying. CONCLUSION: The nervous system is endowed with a limited number of genes and of types of molecules and, especially during development, its functional repertoire, at least from an observable point of view, is also limited. Therefore, ample genotyping capabilities are necessary to avoid erring in the process of diagnostic attribution because of phenocopying.

Calcium Channels↗

Prostacyclin in the management of pulmonary hypertension after heart transplantation.

Right ventricular failure after heart transplantation has been well documented as a major determinant of patient outcome. In 50 patients undergoing orthotopic heart transplantation, nine male patients with an average age of 41 years had in the immediate postoperative period a syndrome that consisted of low cardiac index, high right atrial and pulmonary artery pressures, and high pulmonary vascular resistance. The preoperative data showed: right atrial pressure, 9 +/- 6 mm Hg; pulmonary pressure, 38 +/- 10 mm Hg; cardiac index, 1.6 +/- 0.4 L/min/m2; pulmonary vascular resistance, 466 +/- 91 dynes/sec/cm-5; pulmonary wedge pressure, 15 +/- 6 mm Hg; and systemic vascular resistance, 2089 +/- 290 dynes/sec/cm-5. The immediate postoperative data revealed: right atrial pressure, 17 +/- 5; pulmonary artery pressure, 32 +/- 8; cardiac index, 2.2 +/- 0.7; pulmonary vascular resistance, 421 +/- 368; pulmonary wedge pressure, 15 +/- 6; systemic vascular resistance 1318 +/- 263. All of these patients were receiving inotropic and vasodilator drugs with no improvement after volume challenge. Prostacyclin was started, and the dose increased from 0.5 to 5.0 ng/kg/min, until an increase in cardiac index and a reduction in pulmonary resistance were achieved. The final profile was right atrial pressure, 12 +/- 5; pulmonary artery pressure, 24 +/- 6; cardiac index, 3.7 +/- 1.2; pulmonary vascular resistance, 122 +/- 42; pulmonary wedge pressure, 14 +/- 4; systemic vascular resistance, 870 +/- 263. The use of prostacyclin enabled the weaning of other drugs within a 48-hour period with no side effects and no worsening of the hemodynamic conditions after discontinuation of prostacyclin.

Adult↗